Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Hepatitis C Market 2016 Share, Trend, Segmentation and Forecast to 2020

Thursday, November 10, 2016 0:06
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period. 

Request a sample report @ https://www.wiseguyreports.com/sample-request/529619-hepatitis-c-market-forecast-hepatitis-c-clinical-trials-global

This is 3rd edition report on Hepatitis C Drugs Industry. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials – Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape. 

1. Hepatitis C Drugs Market & Forecast (Chapter 2) 
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3) 
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4) 
4. Hepatitis C Deals & Acquisitions (Chapter 5) 
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6) 

Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3) 

1. Pegasys 
2. Pegintron 
3. Incivek 
4. Victrelis 
5. Olysio 
6. Sovaldi/Harvoni 
7. HCV Franchise 
8. Viekira Pak 

Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4) 

1. Drug A (Merck & Co. Inc.) 
2. Drug B (Merck & Co. Inc.) 
3. Drug C (Bristol-Myers Squibb) 

Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5) 

1. AbbVie 
2. Bristol-Myers Squibb (BMS) 
3. Gilead Sciences 
4. Merck & Co. Inc. 
5. Tibotec/Janssen Therapeutics 

Data Sources 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. 

Primary sources include industry surveys and telephone interviews with industry experts. 

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.         

Complete report details @ https://www.wiseguyreports.com/reports/529619-hepatitis-c-market-forecast-hepatitis-c-clinical-trials-global      

Key points in table of content

1. Executive Summary

2. Hepatitis C Drugs – Market & Forecast

3. Hepatitis C – Approved Drugs Sales & Forecast 
    3.1 Pegasys Sales & Forecast 
    3.2 Pegintron Sales & Forecast 
    3.3 Incivek Sales 
    3.4 Victrelis Sales & Forecast 
    3.5 Olysio Sales & Forecast 
    3.6 Sovaldi / Harvoni Sales & Forecast 
    3.7 HCV Franchise Sales & Forecast 
    3.8 Viekira Pak Sales & Forecast

4. Hepatitis C – Pipeline Drugs Sales Forecast 
    4.1 Drug A of (Merck & Co. Inc.) 
    4.2 Drug B of (Merck & Co. Inc.) 
    4.3 Drug C of (Bristol-Myers Squibb)

5. Hepatitis C – Deals & Acquisitions

6. Hepatitis C – Company Wise Clinical Trials Analysis 
    6.1 AbbVie – Clinical Trials 
      6.1.1 Phase III 
      6.1.2 Phase II 
      6.1.3 Phase I 
    6.2 Bristol-Myers Squibb (BMS) – Clinical Trials 
      6.2.1 Phase III 
      6.2.2 Phase II 
    6.3 Gilead Sciences – Clinical Trials 
      6.3.1 Phase II 
    6.4 Merck & Co. Inc. – Clinical Trials 
      6.4.1 Phase IV 
      6.4.2 Phase III 
      6.4.3 Phase II 
      6.4.4 Phase I 
    6.5 Tibotec / Janssen Therapeutics – Clinical Trials 
      6.5.1 Phase IV 
      6.5.2 Phase III 
      6.5.3 Phase II 
      6.5.4 Phase I

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=529619

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.